Search

Primary liver cancer is one of the most common malignant tumors in China and has been a major threat to human health. With advances in the basic and clinical research on primary liver cancer in recent years, the diagnosis and treatment methods for primary liver cancer have been constantly enriched. Traditional Chinese medicine (TCM) has played an important role in the diagnosis and treatment of primary liver cancer, but there is still a lack of standardized guidelines for syndrome differentiation-based treatment and response evaluation criteria. In order to further standardize the TCM diagnosis and treatment of primary liver cancer, the drafting group developed this guideline through literature review, expert interviews, questionnaire surveys, and consensus meetings based on the requirements of TCM standardization and related technical guidance documents, so as to provide a reference for clinicians. This guideline has been approved by China Association of Chinese Medicine, with the standard number of T/CACM1575—2024. [ABSTRACT FROM AUTHOR]

Copyright of Journal of Clinical Hepatology / Linchuang Gandanbing Zazhi is the property of Journal of Clinical Hepatology and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

At present, the treatment of primary liver cancer is mainly based on modern medicine. Studies have found that traditional Chinese medicine (TCM) can promote the apoptosis of hepatoma cells and regulate the immunity of human body by affecting multiple critical pathways involved in the development and progression of tumor. TCM plays an irreplaceahle role in the treatment of liver cancer, and the focus on the etiology and pathogenesis of liver cancer is the key to achieving good efficacy. Although there are still no ideal anti - HBV drugs in TCM, intervention on the etiologies of dampness, heat, phlegm, toxin, stasis, and deficiency and the change in struggle between vital Qi and pathogen during each stage of disease progression may delay or even prevent disease progression, which is the treatment based on etiology and pathogenesis and is the theory that "treatment should focus on the principal cause of a disease". In clinical practice, modern medical treatment combined with TCM can improve patients' quality of life and reduce tumor recurrence, and TCM combined with sorafenib has stronger efficacy and fewer side effects. Meanwhile, further studies are needed to explore how integrated traditional Chinese and Western medicine therapy exerts a therapeutic effect on liver cancer and the detailed mechanism of action of TCM in the treatment of liver cancer. [ABSTRACT FROM AUTHOR]

In recent years, the number of drug - induced liver injury ( DILI) eases is increasing year by year due to unreasonable drug use in clinical practice, unclear composition of healthcare products and dietary supplements, and a lack of drug safety knowledge, and DILI has become a major cause of liver failure and liver transplantation. DILI has complex pathogenesis, and medical institutions are paying more and more attention to DILL Related animal and cell experiments are being conducted all over the world, and advances have been made in metabolic pathways, immune mechanism, mitochondrial abnormality, and genetics of DILL In - depth research on various pathogeneses and their association helps to reveal the true pathogenesis of DILL With reference to the articles on the pathogenesis of DILI in China and foreign countries, this article elaborates on the current research status of the pathogenesis of DILI and provides a reference for clinical treatment and basic research. [ABSTRACT FROM AUTHOR]

Copyright of Journal of Clinical Hepatology / Linchuang Gandanbing Zazhi is the property of Journal of Clinical Hepatology and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Journal of Beijing University of Traditional Chinese Medicine is the property of Journal of Beijing University of Traditional Chinese Medicine and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Journal of Clinical Hepatology / Linchuang Gandanbing Zazhi is the property of Journal of Clinical Hepatology and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Objective To investigate the traditional Chinese herbs and core prescriptions commonly used by Professor Qian Ying in the syndrome differentiation - based treatment of primary liver cancer, and to guide clinical medication. Methods A retrospective analysis was performed for the clinical data of the patients diagnosed and treated by Professor Qian Ying. A descriptive analysis was performed to analyze Professor Qian Ying's clinical medication and prescriptions in the treatment of primary liver cancer, and the complex network and clustering with point mutual information were used to analyze the complex association between multiple traditional Chinese herbs. Results A total of 111 patients with primary liver cancer were enrolled. There were 287 visits, 287 prescriptions, and 132 traditional Chinese herbs in total. The core herbs used by Professor Qian Ying were Visci herba, raw Astragalus membranaceus, Salvia miltiorrhiza, Oldenlandia diffusa, and Polygoni Orientalis Fructus, and this result was consistent with the composition of Huqi powder developed by Professor Qian Ying. The prescriptions commonly used included Huqi powder, Shengmai decoction, and Xiaoyao powder. Conclusion Salvia miltiorrhiza is the special herb used by Professor Qian Ying in the treatment of primary liver cancer and Huqi powder developed by Professor Qian Ying is the commonly used prescription. [ABSTRACT FROM AUTHOR]